This site is intended for health professionals only!

Alemtuzumab extension confirms safety and efficacy

teaser

An extension phase study has shown that the monoclonal antibody, alemtuzumab, remains significantly superior to inferon-beta for treatment of early, active, relapsing–remitting multiple sclerosis, with safety concerns as reported previously.

Continued follow-up for five years of 198 of the 334 patients originally randomised to treatment for the CAMMS223 study showed a 72% reduction in sustained accumulation of disability and a 69% reduction in rate of relapse, compared with interferon-beta (pp<0.0001).

By month 60, patients receiving alemtuzumab had an average of 0.11 relapses per year, compared with 0.35 relapses among patients receiving interferon-beta.

Serious infections were more common in patients receiving alemtuzumab (7%) than those receiving interferon-beta (3%).

Thyroid disorders were also more common with alemtuzumab (30%) than interferon-beta (4%).

Likewise immune thrombocytopenia was more common in patients receiving alemtuzumab (3%) than interferon-beta (0.9%).

Goodpasture disease occurred in one patient on alemtuzumab, 39 months after the second annual cycle.

The researchers conclude: “Through extended follow-up, alemtuzumab remained significantly more efficacious than IFN-beta-1A, with a safety profile consistent with previous reports.”

Neurology

 



Most read




Latest Issue

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine
Share this story: